Researchers propose that BPC157, a protective peptide found in gastric juices, may hold promise as a new treatment for cancer-related muscle wasting and weight loss.
>50% of terminal cancer patientsare affected by cachexia, yet no effective treatment currently exists
What the researchers found
This review proposes BPC157, a cytoprotective peptide isolated from gastric juices, as a potential therapeutic agent for cancer cachexia. The authors present preclinical evidence that BPC157 may rescue from cancer cachexia through its explored modes of action, positioning it as a candidate for clinical trials.
Why it matters
Cancer cachexia affects over 50% of terminal cancer patients and accounts for up to 20% of cancer deaths, yet no effective treatment exists. Identifying a novel peptide-based therapeutic candidate like BPC157 could address this urgent unmet medical need.
The numbers in context
50% of terminal cancer patients affected · up to 20% of cancer deaths attributable to cachexia
How the study worked
Literature review synthesizing preclinical evidence for BPC157 in cancer cachexia, including exploration of its mechanisms of action.
Who was studied
Preclinical models (review of existing literature); no direct human subjects
What this study cannot tell us
This is a review paper proposing BPC157 as a candidate, not a clinical trial. The evidence presented is preclinical and has not yet been validated in human studies.
How to read the evidence
This is a narrative review paper that synthesizes preclinical evidence and proposes a hypothesis. It does not present new experimental data or clinical trial results, placing it at the lower end of the evidence hierarchy.
When this study was published
Published in 2018, this review outlines a research direction for BPC157 in cachexia. Since publication, interest in BPC157 research has continued, though clinical trial data for this specific application remains limited.
The bigger picture
Cancer cachexia remains one of oncology's most challenging problems, with no approved targeted therapy. The exploration of peptide-based agents like BPC157 represents a shift toward leveraging the body's own protective molecules. If validated in clinical trials, BPC157 could become part of multimodal treatment packages combining nutritional, anti-inflammatory, and novel cytoprotective approaches.
Questions still open
- Will BPC157 show the same anti-cachexia effects in human clinical trials as seen in preclinical models?
- What is the optimal route of administration and dosing for BPC157 in cancer cachexia patients?
- Could BPC157 interact with or enhance existing cancer treatments without promoting tumor growth?
Common questions
What is cancer cachexia and why is it so dangerous?
What is BPC157 and why might it help with cachexia?
Read the original research
BPC157 as Potential Agent Rescuing from Cancer Cachexia.
Current pharmaceutical design, 24(18), 1947-1956
Citation
Kang, Eun A; Han, Young-Min; An, Jeong Min; Park, Yong Jin; Sikiric, Predrag; Kim, Deok Hwan; Kwon, Kwang An; Kim, Yoon Jae; Yang, Donghwa; Tchah, Hann; Hahm, Ki Baik. (2018). BPC157 as Potential Agent Rescuing from Cancer Cachexia.. Current pharmaceutical design, 24(18), 1947-1956. https://doi.org/10.2174/1381612824666180614082950